Brokerages Set Smith & Nephew SNATS, Inc. (NYSE:SNN) PT at $30.93

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $30.9250.

SNN has been the subject of a number of research analyst reports. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a report on Monday, May 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. Canaccord Genuity Group lowered their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several large investors have recently added to or reduced their stakes in SNN. Royal Bank of Canada increased its position in Smith & Nephew SNATS by 16.7% in the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock worth $9,657,000 after buying an additional 48,784 shares during the period. Goldman Sachs Group Inc. increased its position in Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares during the period. Focus Partners Wealth boosted its position in Smith & Nephew SNATS by 59.8% during the 1st quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 7,277 shares during the period. Cetera Investment Advisers boosted its position in Smith & Nephew SNATS by 5.9% during the 2nd quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock worth $543,000 after acquiring an additional 983 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Smith & Nephew SNATS by 219.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,261 shares of the medical equipment provider’s stock worth $161,000 after acquiring an additional 3,613 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Down 0.3%

Shares of NYSE SNN opened at $30.43 on Wednesday. Smith & Nephew SNATS has a twelve month low of $28.40 and a twelve month high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. The business has a 50 day simple moving average of $31.81 and a 200-day simple moving average of $33.06.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion during the quarter. Analysts expect that Smith & Nephew SNATS will post 2.25 EPS for the current year.

Smith & Nephew SNATS Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a $0.482 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.